FICAN Science Webinar with Prof. Pekka Taimen

9.12.2026

Päivämäärä
09.12.2026
Aika
15:00 - 16:00
Sijainti
etätapahtuma
Organisaatio
FICAN West.
Yhteyshenkilö
info@fican.fi

Welcome to the next FICAN Science Webinar with Prof. Pekka Taimen (University of Turku & Turku University Hospital)!

When: Wed 9.12.2026 at 15:00–16:00
Where: Online / Join the meeting here (Teams)

Chair: prof. Panu Jaakkola

This time the seminar is hosted by FICAN West.

These nationwide webinars provide a platform to share new scientific findings, highlight recent advances in cancer research, and foster collaboration among cancer researchers and clinicians across Finland.

Abstract

Pekka Taimen, MD, PhD, is Professor of Molecular Pathology at the Institute of Biomedicine, University of Turku, and Chief Physician at the Department of Pathology, Turku University Hospital. His translational pathology research group focuses on biomarkers, steroidomics, and patient-derived cell culture models of bladder cancer. Their research on prostate cancer aims to improve diagnostic accuracy and risk stratification by integrating MRI/PET imaging with histopathological data, while lung cancer research has focused on cancer genomics and predictive biomarkers. In addition, Taimen’s laboratory investigates the pathobiology of familial cardiomyopathy caused by pathogenic variants in the LMNA gene, which encodes the nuclear intermediate filament proteins known as lamins.

In this webinar, Taimen will present their recent advances in bladder cancer research, including the development of patient-derived cell culture models for drug sensitivity testing, as well as projects involving steroid hormone and transcriptomic profiling.

Relevat references from the speaker for this talk:

  • Saarikoski K, Askari A, Erkkilä S, Keski-Oja T, Vainio P, Nurminen A, Lamminen T, Suhonen J, Rantala JK, Boström PJ, Kettunen K, Taimen P, Turku Prostate Cancer Consortium (2026). Patient-derived conditionally reprogrammed cells for bladder cancer modeling and drug sensitivity assessment. npj Precision Oncology, in press.
  • Askari A, Mahmoudian M, Lamminen T, Heuser V, Koskinen I, Mirtti T, Elo LL, Schleutker J, Taimen P, Boström PJ (2026). Prediction of platinum-based neoadjuvant chemotherapy response in muscle-invasive bladder cancer using a multifaceted approach. Scientific Reports, 16:36990. https://doi.org/10.1038/s41598-026-64713-3
  • Kettunen K, Mathlin J, Lamminen T, Laiho A, Häkkinen MR, Auriola S, Elo LL, Boström PJ, Poutanen M, Taimen P (2024). Profiling steroid hormone landscape of bladder cancer reveals depletion of intratumoural androgens to castration levels: a cross-sectional study. eBioMedicine 108:105359. https://10.1016/j.ebiom.2024.105359
  • Kettunen K, Boström PJ, Lamminen T, Heinosalo T, West G, Saarinen I, Kaipio K, Rantala J, Albanese C, Poutanen M, Taimen P (2019). Personalized drug sensitivity screening for bladder cancer using conditionally reprogrammed patient-derived cells. European Urology 76:430-434. https://doi.org/10.1016/j.eururo.2019.06.016

For more information on the FICAN science webinar series, please contact info@fican.fi

Finnish Cancer Center FICAN 

PL 700, 00029 HUS | Haartmaninkatu 8, Helsinki  

info@fican.fi   

www.fican.fi